SOPHiA GENETICS SA

Good morning. My name is Angeline, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sophia Genetics fourth quarter and full year 2025 earnings conference call. At this time, all participants are in listen-only mode. Following the presentation, there will be question and answer session. Should you require any operator assistance, you may press star zero. I will now turn the conference call over to Colin Zenger, Sophia Genetics VP of Strategy, you may begin.

Thank you, and good morning, everyone.

Welcome to the Sophia Genetics fourth quarter and full year 2025 earnings conference call. Joining me today to discuss the results are Dr. Yurgi Kamblong, our co-founder and chief executive officer, Ross Mukin, our company president, and George Cardosa, our chief financial officer. I'd like to remind you that management will make statements during this call that are forward-looking statements within the meetings of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding those risks, uncertainties, and factors that could cause results to differ appears in the press release issued by Sophia Genetics today and in the documents and reports filed by Sophia Genetics from time to time with the Securities and Exchange Commission. During this call, we will present both IFRS and non-IFRS financial measures, A reconciliation of IFRS and non-IFRS measures is included in today's earnings press release, which is available on our website.